GLI1 and neoplasm: However, a significant association was not observed between strength of GLI1 repression and odds of tumor response (CR+PR), with hazard ratio (HR; 95% CI, P-value) for low vs high tumor inhibition of 1.4 (0.5–3.8, P = 0.4838) and 0.8 (0.3–2.0, P = 0.6627), for the 200 and 800 mg groups, respectively (Supplementary Table 3).